Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin‐II Formation: Findings From the 45 and Up Study
International Journal of Geriatric Psychiatry · 2026
DOI: 10.1002/gps.70243 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Geriatric Psychiatry, 2026. Verfasst von Eyayaw Ashete Belachew und 3 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy and Pharmacology, UTAS Health, University of Tasmania, Hobart, Australia. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Antihypertensive Agents, Dementia, Angiotensin II. Die Arbeit nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Themen: Demenz
Abstract (Originalsprache)
Background
Hypertension and dyslipidaemia are key modifiable risk factors of dementia, and the combined use of statins and antihypertensive medications (AHMs) may offer protective benefits. However, evidence on specific combinations remains limited. This study examined associations between dementia risk and the use of statins with angiotensin‐II (Ang‐II) promoting AHMs (drugs that increase Ang‐II formation) compared with statins combined with Ang‐II suppressing AHMs (drugs that decrease Ang‐II formation).
Methods
This was a prospective study using data from the 45 and Up Study cohort, a large population‐based cohort in New South Wales, Australia. Participants aged ≥ 45 years with hypertension and dyslipidaemia were included if they had concurrent statin and AHM use. Exposure groups were defined as either users of statins and Ang‐II promoting AHMs (angiotensin II receptor blockers [ARBs], thiazides, and dihydropyridine calcium channel blockers [DHP CCBs]) or statins and Ang‐II suppressing AHMs (angiotensin‐converting enzyme inhibitors [ACEIs], beta‐blockers [BBs], and non‐DHP CCBs). Medication exposure was determined based on a proportion of days covered (PDC ≥ 80%). Baseline characteristics of the two groups were balanced using 1:1 pair propensity score matching. The Cox proportional hazards model was used to estimate hazard ratios (HRs) adjusted for diet, physical activity, comorbidities, and concomitant medications.
Results
Among 34,610 matched participants (17,305 per group; a mean age [standard deviation (SD)] of 65.8 (8.8) years; a mean follow‐up (SD) of 12.4 (5.1) years), use of a statin plus Ang‐II promoting AHM was associated with a 12% lower dementia risk (HR, 0.88; 95% CI, 0.79–0.98) and 13% lower all‐cause mortality (HR, 0.87; 95% CI, 0.82–0.93) compared to statin plus Ang‐II suppressing AHM combinations. Combinations of rosuvastatin or atorvastatin with Ang‐II promoting AHMs (HR, 0.43; 95% CI, 0.36–0.50 and HR, 0.74; 95% CI, 0.64–0.84, respectively) conferred greater benefit compared with simvastatin combined with Ang‐II promoting AHMs. The effects were consistent across both sexes, with the protective association observed only in the 65–74‐year age group, and combinations involving ARBs demonstrated superior benefit compared to those with ACEIs. Findings were robust across sensitivity analyses, including applying a competing‐risks model for death.
Conclusions
Combined therapy with a statin plus Ang‐II promoting AHMs, particularly rosuvastatin or atorvastatin with an ARB, was associated with lower dementia risk, suggesting cognitive benefits may inform therapy selection. Future randomised trials should confirm these findings and explore underlying mechanisms.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy and Pharmacology, UTAS Health, University of Tasmania, Hobart, Australia.
- Department of Clinical Pharmacy, School of Pharmacy, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia.
ORCID-Profile: Eyayaw Ashete Belachew, Gregory M Peterson
Zitieren
APA
Belachew, E. A., Peterson, G. M., Salahudeen, M. S., & Bezabhe, W. M. (2026). Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin‐II Formation: Findings From the 45 and Up Study. International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.70243
Vancouver
Belachew EA, Peterson GM, Salahudeen MS, Bezabhe WM. Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin‐II Formation: Findings From the 45 and Up Study. International Journal of Geriatric Psychiatry. 2026. doi:10.1002/gps.70243
BibTeX
@article{Belachew2026,
author = {Belachew, Eyayaw Ashete and Peterson, Gregory M and Salahudeen, Mohammed S and Bezabhe, Woldesellassie M},
title = {Dementia Risk With Combined Statin and Antihypertensive Drugs That Increase Versus Decrease Angiotensin‐II Formation: Findings From the 45 and Up Study},
journal = {International Journal of Geriatric Psychiatry},
year = {2026},
doi = {10.1002/gps.70243}
}
EUVIMED